drugset
drugset / Trial / NCT05592418

Study to Evaluate the Efficacy and Safety of Ampligen in Patients With Post-COVID Conditions

NCT05592418 ↗

Phase 2 Completed 80 enrolled AIM ImmunoTech Inc. Amarex Clinical Research · collab
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to assess the efficacy and safety of Ampligen® administered twice weekly by intravenous (IV) infusions in subjects experiencing the Post-COVID Condition of fatigue.

Timeline

Start
2023-06-30
Primary completion
2023-11-17
Completion
2023-11-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Rintatolimod Oligonucleotide (other) 100 mg Intravenous
Subject Rintatolimod Oligonucleotide (other) 400 mg Intravenous

Indications

long COVID-19